Marinomed Biotech AG Seeks Court Restructuring amid Market Challenges

On July 22, 2026, Marinomed Biotech AG, an Austrian biotech firm, announced initiating court restructuring proceedings without self-administration, following an announcement made on July 16. This action stems from the sudden termination of their liquidity services contract with Raiffeisen Bank International, impacting the market performance of Marinomed's shares.

The immediate effect is a potential reduction in short-term liquidity and wider bid-ask spreads, though the shares' tradability remains stable. Marinomed's management is actively seeking a new market-making agreement to address these concerns.

Given these developments, Marinomed has delayed its 2026 half-year financial report, initially set for release in September. The company continues to develop its innovative therapeutic solutions based on the Marinosolv® platform.